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To the Editor
Myelodysplastic syndromes (MDS) are bone marrow neo-
plasias that involve mutations in genes affecting various cell
pathways [1]. Both clonal evolution and the type of somatic
mutations appear to be associated with response to treat-
ment [1, 2]. Response to hypomethylating agents possibly
correlates with mutations in TET2 [3], TP53 [4], and
mutation burden [5]. Erythroid response to erythropoiesis-
stimulating agents (ESAs) has also been linked to mutation
burden [6]. Recently, luspatercept has been shown to
enhance late-stage erythropoiesis in non-del(5q) MDS with
ring sideroblasts regardless of mutational status [7].
Lenalidomide therapy has previously been investigated
in MDS-005 (NCT01029262); a randomized, phase 3 trial
of ESA-refractory or -ineligible patients with lower-risk
non-del(5q) MDS [8]. Previous studies investigating mar-
kers of response to lenalidomide, alone or in combination
with ESAs, lacked statistical power and require independent
validation [9, 10]. We carried out an exploratory investi-
gation into the relationship between gene mutations and
response to lenalidomide in patients from the MDS-
005 study.
Efficacy endpoints from the MDS-005 trial were analyzed
according to gene mutation status [11]. Gene expression
analysis was performed at baseline as a primary endpoint of
the MDS-005 study, other analyses were exploratory end-
points. DNA was isolated from bone marrow mononuclear
cells (n= 177) or whole blood (n= 21) collected at screening
from consenting patients with adequate tissue for exploratory
biomarker analysis. Targeted next-generation sequencing of
56 genes was performed at the Munich Leukemia Laboratory
(Supplementary Table 1).
Baseline characteristics of the biomarker cohort (N= 198;
130/68 received lenalidomide/placebo) were generally com-
parable to those of patients not included (Supplementary
Fig. 1; Supplementary Table 2). Within the biomarker cohort,
baseline characteristics were well balanced between patients
receiving lenalidomide and those receiving placebo (Sup-
plementary Table 3). Baseline characteristics of biomarker
cohort patients by ASXL1 mutation status are shown in
Supplementary Table 4. In total, 173 (87.4%) harbored at
least 1 mutation in the 56 genes assessed (Supplementary
Table 5). Fifty-five patients (27.8%) had a single mutation,
63 (31.8%) had 2 mutations, and 55 (27.8%) had >2 muta-
tions. Mutations were detected in 30 of the 56 genes assessed
(Supplementary Fig. 2a). The most commonly observed gene
mutations were SF3B1 (58.6% of patients), TET2 (33.0%),
ASXL1 (23.2%), and DNMT3A (13.6%). The most frequently
observed co-mutations were SF3B1 and TET2 (22.7%),
SF3B1 and DNMT3A (10.1%), SF3B1 and ASXL1 (9.6%),
and TET2 and ASXL1 (8.6%) (Supplementary Fig. 2b);
99.1% of patients with SF3B1 mutations had ring side-
roblasts ≥5% (Supplementary Table 6). The relationship
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between mutation status and cytogenetic abnormalities at
baseline is shown in Supplementary Table 7.
Among lenalidomide-treated patients, the proportion of
patients achieving red blood cell transfusion independence
(RBC-TI) ≥8 weeks was significantly lower in those with
ASXL1 mutations than those without (10.3% vs. 31.7%; p=
0.031) (Fig. 1a). The proportion of patients achieving RBC-
TI ≥8 weeks was nominally higher in those with DNMT3A
mutations than in those without (43.8% vs. 24.6%; p=
0.133). RBC-TI ≥8 weeks was achieved by 42.9% of patients
with bothDNMT3A and SF3B1mutations (which co-occurred
in most patients), 1 of 2 patients (50.0%) with DNMT3A only,
27.1% of patients with SF3B1 only, and 21.8% of patients
with neither DNMT3A nor SF3B1 mutations. Eleven patients
(5.6%) had EZH2 mutations; of the 9 receiving lenalidomide,
4 (44.4%) achieved RBC-TI ≥8 weeks, versus 31 of 121
(25.6%) patients without EZH2 mutations (p = 0.250)
(Fig. 1a). Mutations in other genes were not significantly
associated with response to lenalidomide.
No specific single mutation was associated with
achievement of RBC-TI ≥24 weeks with lenalidomide,
although patients with ASXL1 mutations had a nominally
lower rate of RBC-TI ≥24 weeks than those without ASXL1
mutations (6.9% vs. 21.8%; p= 0.101) (Fig. 1b). Mutation
status of the 12 patients who achieved RBC-TI ≥52 weeks is
shown in Supplementary Table 8. There was no association
between mutation status and duration of RBC-TI in patients
treated with lenalidomide.
The number of mutations present did not appear to cor-
relate with response, and no relationship was found between
the variant allele frequency of mutations and response rates
(Supplementary Fig. 3). Of 27 lenalidomide-treated patients
evaluable for cytogenetic response, 5 (18.5%) achieved
cytogenetic complete response and 4 (14.8%) had cytoge-
netic partial response (PR) (Mutations status: Supplemen-
tary Table 9). Presence of an A/G polymorphism at
rs1672753 in the CRBN gene was not associated with
response in the MDS-005 study population. No patients
evaluated in our study had a CSNK1A1 mutation.
Overall survival (OS) by treatment group and ASXL1
mutation status is shown in Fig. 2a. Mutations in the
ASXL1 gene were associated with significantly shorter
median OS, regardless of treatment group (log-rank p <
0.0001). Among patients with ASXL1 mutations, median
OS was 2.0 years (95% confidence interval (CI) 1.5–3.1)
with lenalidomide and 2.1 years (95% CI 0.9–not estim-
able (NE)) with placebo (p= 0.576). Shorter OS in
patients with ASXL1 mutations was confirmed with a Cox
proportional hazards model (hazard ratio (HR) 2.6 [95%
CI 1.5–4.6]) controlling for clinical covariates including
baseline erythropoietin (EPO), blast percentage, and
Revised International Prognostic Scoring System (IPSS-
R) risk. The presence of DNMT3A mutations had no
significant effect on OS in patients receiving placebo (log-
rank p= 0.3228) (Fig. 2b); however, there was a trend
toward longer median OS with lenalidomide (NE [95% CI
2.0 years–NE]) compared with placebo (1.6 years [95%
CI 0.6–NE]) (p= 0.123). Mutations in SF3B1 and TET2
had no significant effect on OS.
The presence of a mutation in any of 5 genes previously
linked to poor prognosis (that is ASXL1, ETV6, EZH2,
RUNX1, and TP53) [12] was associated with shorter median
OS (log-rank p= 0.0018) (Fig. 2c). Median OS was 2.1
years (range 1.7–3.1) in lenalidomide-treated patients with
mutations in any of the 5 genes versus NE (NE–NE) in non-
mutated lenalidomide-treated patients (p= 0.0003).
In patients receiving lenalidomide, a higher number of
mutations was significantly associated with shorter median
OS (log-rank p= 0.0005) (Fig. 2d). Median OS was NE
in patients with 0–3 mutations and 1.7 years (range 0.6–NE)
in patients with ≥4 mutations.
Patients with ≥4 mutations were more likely to have a
high serum EPO level (>500 mU/ml) than patients with
fewer mutations (p= 0.0190). Int-1-risk patients with high
EPO levels were more likely to have ≥4 mutations than
those with low EPO levels (10/16 patients [62.5%] versus 6/
16 patients [37.5%]; p= 0.0962); there was no significant
difference for Low-risk patients (3/6 patients [50.0%] vs. 3/
6 patients [50.0%]; p= 0.3403). Int-1-risk patients with
high EPO levels were also more likely to have mutations
in any of the 5 genes previously linked to poor prognosis
Fig. 1 Proportion of patients treated with lenalidomide
who achieved RBC-TI according to gene mutation status. RBC-
TI ≥8 weeks (a) and ≥24 weeks (b). Dotted lines represent response
rates in all patients treated with lenalidomide (26.9% and 17.5% for
RBC-TI ≥8 and ≥24 weeks, respectively). RBC-TI red blood cell
transfusion independence.
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(ASXL1, ETV6, EZH2, RUNX1, and TP53) [12] compared to
those with low EPO levels (60.6% vs. 39.4%; p= 0.0102);
there was no significant difference for Low-risk patients.
The high prevalence of mutations and mutational profile
are consistent with results from a previous analysis of
patients with MDS [1, 2, 12]. The effect of ASXL1 mutations
on response rate to lenalidomide and OS, regardless of
treatment, is consistent with prior reports showing an adverse
prognostic effect of ASXL1 mutations [2, 12, 13]. Also, the
trend towards improved response to lenalidomide in patients
with DNMT3A mutations is consistent with results from a
trial of patients with non-del(5q) MDS in which DNMT3A
mutations predicted better response [10]. Patients with
DNMT3A mutations have higher rates of progression to acute
myeloid leukemia (AML) [14]. It may therefore be that the
trend towards improved OS in DNMT3A-mutated patients
receiving lenalidomide in this study was a result of a
reduction in the rate of AML progression.
The association of increased mutation burden with worse
OS is consistent with previous reports of a link with shorter
leukemia-free survival [1]. Patients with ≥4 mutations were
more likely to have a high serum EPO level (>500 mU/ml),
a negative prognostic marker associated with a lower
probability of response to treatment [8, 15]. High serum
EPO level was associated with the presence of mutations in
any of 5 poor-prognosis genes (ASXL1, ETV6, EZH2,
RUNX1, and TP53) [13] and specifically ASXL1. Taken
together with the observed association between ASXL1
mutations and low response rate to lenalidomide, this pro-
vides further insight into previous observations that patients
with high baseline EPO level have a lower probability of
responding to lenalidomide [8].
Limitations of this analysis include the confounding
effects of co-mutations on outcomes and the relatively small
and heterogeneous group of patients.
A better understanding of how somatic mutations influ-
ence lenalidomide response may help identify patients with
lower-risk non-del(5q) MDS who are most likely to respond
to lenalidomide therapy. Efforts are currently ongoing to
incorporate mutations into the IPSS-R to improve its
prognostic value [13]. Currently, there are no unequivocal
genetic markers of response to non-therapeutic targets, such
Fig. 2 Overall survival by treatment group and mutation status. For ASXL1 (a), DNMT3A (b), any 1 of 5 genes in the Bejar 5-gene mutation
signature (c), and number of mutations (d). CI confidence interval, LEN lenalidomide, NE not estimable, OS overall survival.
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as lenalidomide for lower-risk non-del(5q) MDS. However,
our finding that ASXL1 mutations negatively affect out-
comes with lenalidomide is relevant, as negative prognostic
factors are not always predictive of poor response, as was
demonstrated by the contrasting finding for TP53 in MDS
patients treated with decitabine [4]. Thus, identifying pre-
dictive markers of response to lenalidomide in non-del(5q)
MDS patients remains an ongoing challenge.
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